|
Growth Hormone Debate
|
 |
|
Trans-D & IGF1
|
|
|
|
DVD...
|
|
|
 |
We Challenge You to Look & Decide For Yourself
|
 |
|
Chapter 26 from Anti-Aging Medical Therapeutics Vol. 5
|
|
The Inter-Relationship Between
Growth Hormone, IGF-1, and Cancer
Rashid A Buttar DO, FAAPM, FACAM, FAAIM
Visiting Scientist, North Carolina State University
Chapter 26 from "Anti-Aging Medical Therapeutics Vol. 5"
INTRODUCTION
The benefits of growth hormone (GH, also known as human growth hormone or hGH) have received
increasing attention from not only the media but the medical profession as well, as a result
of studies indicating GH may have the ability to restore a more youthful physiology and
enhance the quality of life. However, there is controversy centered on the possibility that
maintaining youthful GH levels may actually be harmful in the long run and may result in
shortening life span by inducing cancer.
Intuitively, it is obvious that naturally occurring endogenous GH released within
physiological parameters itself could not possibly cause cancer. The reasoning for this
statement
is actually quite simple because all mammalian species achieve the maximum level of GH
levels
when reaching late adolescence and young adulthood. If endogenous GH were actually a cause
of cancer, then all mammalian species including man would have the highest incidence of
cancer during late adolescence and young adulthood. However, as we all know, this is not
what occurs.
So, what then causes cancer? The answer unfortunately, is more than a little involved. We
know that a minimum of 75% of all cancers have been shown to have environmental etiologies.
In addition, there are certain factors that predispose individuals to have a higher
propensity to develop uncontrolled cellular proliferation and induce the suppression of
apoptosis, leading to oncogenesis or the formation of cancer. In addition, we know that the
incidence of cancer generally occurs later in life as opposed to late adolescence and young
adulthood when we have
the highest levels of GH.
The first foundational objective essential to gaining an insight into these issues is to
clearly understand the hypothalamic-pituitary axis. More often than not, we forget the
physiological
safety mechanisms designed within our systems to protect us. In this case, we refer to the
negative inhibitory feedback loop designed to decrease or stop the release of endogenous GH
when levels exceed the physiological range. This inhibitory feed back loop plays a
significant role in the hypothalamic-pituitary axis and realizing its significance is vital
to understanding the advantages of using growth hormone releasing hormone (GHRH) to increase
endogenous GH as
opposed to using exogenous GH.
This will lead to the discussion of why assessing increases in insulin-like growth factor
type1 (IGF-1) as a marker of GH efficacy may not only be unreliable, but a compelling
argument will
be presented that the practice may be nothing more than the perpetuation of a medical myth.
In
fact, conclusive data from multiple sources showing that increases in IGF-1 are conducive to
the propagation of oncogenesis will be presented and then supported by published research.
This
conclusion is very well supported by scientific observation, clinical data, and published
research,
as well as being supported by general physiological concepts - all of which will be
presented later
in this chapter.
Finally, the inter-relationship between GH, GHRH, and IGF-1, as well as how each individual
component correlates with incidence of cancer, will be thoroughly explained. It is
important however, to first discuss the common characteristics of cancer and the various
treatment options available so that all readers have the same foundational knowledge
essential to understanding and conceptually comprehending the material being presented.
Continue Reading
|
|
|
|
|
Study - Journal of Integrative Medicine
|
|
ACCELERATED AND EFFICACIOUS RESULTS USING VARIABLE
SOMATOTROPH AND HYPOTHALAMOTROPH SPECIFIC POLY-PEPTIDE COMBINANTS
UTILIZING A TRANS-DERMAL DELIVERY MECHANISM (TD-GHRH-A) AS AN
ALTERNATIVE TO RECOMBINANT HUMAN GROWTH HORMONE INJECTION THERAPY
Rashid A. Buttar, DO, FAAPM, FACAM
Dean C. Viktora, PhD
Michael E. Quinn, EMT-P
OBJECTIVE
A patient outcome based study was conducted to investigate the possible efficacy of
certain
somatotroph and hypothalamotroph specific poly-peptide combinants which appear to
emulate the action of GHRH resulting in a highly efficacious release of endogenous
GH.
BACKGROUND
Although the GH injections and secretagogues do offer many benefits for the limitations
of
aging, the need for a safer and more effective modality of therapy has long been
warranted.
METHODS
Of the 35 patients that were started on the study, 30 completed the full study. Groups
were
divided into sedentary and athletic groups. A total of 22 subjective criteria were
monitored
including: sense of well being, overall energy, mental clarity, emotional stability,
memory
improvement, mood improvement, skin thickness, skin elasticity, wrinkle disappearance,
new hair growth, skin texture, healing of old injuries, healing of overall injuries,
range of
motion, incidence of illness, body contour change, facial contour change, sexual
frequency,
sexual stamina, libido, quality of erection/arousal, and change in nocturia. Objective
criteria measured were muscle strength, overall energy, exercise endurance and quality
of
sleep. Laboratory data consisting of pre- and post- treatment IGF-1 levels and base line
chemistries were also obtained. Changes were recorded by a self-assessment methodology
utilizing a scale of -5 to +5 with 0 as base line. This accepted modality of evaluation
with
previous precedent having been set was chosen for this patient outcome based
study.
RESULTS
Within the first week, changes experienced were overwhelmingly positive. Improvements
were reported of 282.98% in the female subjects and 352.38% in male subjects. Muscle
strength increased by 81.0%. Endurance increased by 60.0%. Quality of sleep improved
by 92.6%. Overall energy increased by 71.4%. Total mean improvement of all 4 objective
criteria increased by 76.6%. Interestingly, the 3 week post study IGF-1 levels dropped
20.39% within both athletic and sedentary study groups with a 27.16% drop in IGF-1
levels
in the female patients and a 14.61% drop in IGF-1 levels in the male patient population.
CONCLUSIONS
Efficacy based upon subjective criteria was far beyond expectation. Objectively measured
increases in muscular strength conclusively show this TD-GHRH-A (trans-dermal GHRH
analog) to be clinically superior for resistance training as compared to hGH (Human Growth Hormone) injections.
Simplicity of trans-dermal administration also appears to lead to a greater level of
patient
compliance. Substantial improvements in all criteria are further validation of this
TDGHRH-
A (brand name Trans-D Tropin®?) as not only an effective alternative to hGH (Human Growth Hormone)
injections but perhaps a replacement of the more costly, potentially dangerous and less
compliant injection treatments. The lack of correlation between clinical improvement and
increasing IGF-1 levels als o warrants re-evaluation of our currently accepted
understanding
of IGF-1. These results strongly warrant further clinical research of this TD-GHRH-A.
Continue Reading
|
|
|
|
| Results of Double Blind Study |
|
Preliminary Results of Multi-Centered, Double Blind, Placebo Controlled,
Cross-Over Study Evaluating Endogenous hGH (Human Growth Hormone) Levels with Serial hGH (Human Growth Hormone) Radio
-Immunoassay Levels After Trans-Dermal GH Releasing Hormone Analog (Trans-D
Tropin®) Administration.
Rashid Buttar, DO, James Biddle, MD, Rajiv Chandra, MD, Terry Grossman, MD,
Clarence Norris, MD, James Smith, DO, Annette Stoesser, MD, Dean Viktora, PhD
Serial hGH (Human Growth Hormone) radio-immunoassay testing has clearly established rapid and substantial
increases in ENDOGENOUS hGH (Human Growth Hormone) levels with Tran-D Tropin® usage. This tran -dermal GH
Releasing Hormone analog offers the first hope of naturally and conveniently sustaining
youthful levels of hGH (Human Growth Hormone).
The only definitive method for precise evaluation of GH treatment is by DIRECT
MEASUREMENT of ENDOGENOUS hGH (Human Growth Hormone). However, this test usually is not obtained by the
clinician. One reason for this is, up until now, no generally available GH therapeutic
modality has ever been shown to effectively increase ENDOGENOUS hGH (Human Growth Hormone) levels in
a sustainable manner. As a result, the testing of hGH (Human Growth Hormone) has usually been reserved for
evaluation in hGH (Human Growth Hormone) deficiency and short stature syndromes.
Another major reason why hGH (Human Growth Hormone) levels have not been measured as a standard is because
natural physiological release of ENDOG ENOUS hGH (Human Growth Hormone) is pulsatile. Therefore, the very
transitory nature of ENDOGENOUS hGH (Human Growth Hormone) makes it difficult to measure.
The preliminary results of a double blind study demonstrated measurably increased levels
of ENDOGENOUS hGH (Human Growth Hormone) per radio-immunoassay in
117 patients using Trans-D Tropin®. Serum hGH (Human Growth Hormone) levels were drawn at baseline, followed by
a dose of Trans-D Tropin® (experimental
group) or placebo (control group) with subsequent serum levels drawn at 30, 60 and 90
minutes post treatment. Average levels increased o ver 750 within 30 minutes of Trans-D
Tropin® application.
ENDOGENOUS hGH (Human Growth Hormone) levels increased 462% from
baseline to 90 minutes after Trans-D Tropin®
administration during first time use. At 2 weeks,
over 815% increase in ENDOGENOUS hGH (Human Growth Hormone) level were recorded from baseline to 90 minutes
post Trans-D Tropin® application. By week 5, a 1754 increase in ENDOGENOUS hGH (Human Growth Hormone) levels
were achieved within 90 minutes of using Trans-D Tropin®, compared to baseline. Although
every patient did not respond (93.16% response rate), the data was statistically
significant (P<0.001).
In addition to increasing ENDOGENOUS hGH (Human Growth Hormone) levels, Trans-D Tropin® demonstrated change not
generally associated with hGH (Human Growth Hormone) injection therapy. Consistent decrease in Cortisol,
Insulin and IGF-1 levels were noted. The majority of published medical literature and
current research have definitively established the unreliability of IGF-1 as an
indicator of hGH (Human Growth Hormone) therapy efficacy. This study further indicates an actual inverse
relationship between IGF-1 and hGH (Human Growth Hormone) treatment.
Rapid and dramatic improvements in muscle strength, endurance, insomnia, anorexia, and
sense of well being were also noted. Placebo group showed same subjective changes when
crossed over into experimental group. Tran -D Tropin® appear to be not only more
efficacious, but the safety, convenience, cost advantage, compliance and natural
physiological emulation are factors which make it a far more preferable treatment
modality for increasing hGH (Human Growth Hormone) levels than recombinant, synthetic hGH (Human Growth Hormone) injection therapy.
% Change in Endogenous hGH (Human Growth Hormone) by Radio -Immunoassay in 117 Patients
(Change from Baseline to 90 Minutes Over 8 Week Period, Using Trans-D Tropin®)
Drop at 8 wks in hGH (Human Growth Hormone) attributed to
either Somatostatin stimulation or
drop in pituitary reserves due to
sustained GH release. Subjective responses (SF-36 patient outcome based) improved beyond
8 wks. At
18 months, improvements continue. Evidence: Subjective response i intact, despite
minimal hGH (Human Growth Hormone) change
% Change in Endogenous hGH (Human Growth Hormone) Levels Over 8 Wks
|
|
|
|
|
Overall Health
